Clinical trials: Vehicle
Bacterial Conjunctivitis
Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle
The objective of this study is to evaluate the safety of Besivance (besifloxacin ophthalmic suspension, 0.6%) compared to vehicle.
- Trial name
- NCT01175590
- Testing
- Besivance, Vehicle
- Where
- United States
- Volunteers
- 518 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Disease
Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)
The objective of this study is to evaluate the chronic safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs of dry eye disease (DED).
- Trial name
- NCT03873246
- Testing
- OC-01 0.1% 0.6 mg/ml, OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)
- Where
- Mexico
- Volunteers
- 123 people
- Sponsor
- Oyster Point Pharma, Inc.
Heart Failure
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3
This is a double-blind, randomized, two x two crossover (aprepitant vs placebo) during both initiation of Entresto, LCZ696, (50 mg dose) and at steady-state of Entresto (200 mg bid dose or the highest tolerated dose).
- Trial name
- NCT04649229
- Testing
- LCZ 696, Para-aminohippurate, Iohexol
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Yale University
Ocular Discomfort
A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery
The primary objective of this exploratory study is to assess preliminary efficacy and safety of rhNGF when administered as eye drops to patients after cataract and refractive surgery.
- Trial name
- NCT03035864
- Testing
- rhNGF, Vehicle
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Dompé Farmaceutici S.p.A
Seborrheic Keratosis
Study of A-101 for the Treatment of Seborrheic Keratosis
The purpose of this study is to evaluate the safety and dose-response of 2 concentrations of A-101 versus a vehicle control in the treatment of seborrheic keratosis.
- Trial name
- NCT02260180
- Testing
- A-101
- Where
- 4 sites in United States
- Volunteers
- 119 people
- Sponsor
- Aclaris Therapeutics, Inc.
Eyelash Hypotrichosis
Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% compared with vehicle in Japanese adults with hypotrichosis of the eyelashes following chemotherapy treatment.
- Trial name
- NCT01391286
- Testing
- bimatoprost solution 0.03%, bimatoprost vehicle solution
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Allergan
Myopia
CHAMP: Study of NVK-002 in Children With Myopia
Stage 1: To evaluate the safety and efficacy of 2 concentrations of NVK-002 compared to Vehicle (placebo) for slowing the progression of myopia in children over a 3 year treatment period.
- Trial name
- NCT03350620
- Testing
- NVK-002 Concentration 1, NVK-002 Concentration 2
- Where
- 26 sites in United States, Hungary and 4 more
- Volunteers
- 670 people
- Sponsor
- Vyluma, Inc.
Psoriasis Vulgaris
A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris
The purpose of the study is to evaluate the anti-psoriatic effect of LEO 35299 in different formulations, compared to Daivonex® ointment and Daivonex® ointment vehicle, using the psoriasis plaque test modified from the method…
- Trial name
- NCT01580488
- Testing
- B LEO 35299 20 mg/g cream, C LEO 35299 20 mg/g cream, E LEO 35299 10 mg/g solution
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Acne Vulgaris
A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)
This is a multi-center, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, efficacy, and tolerability of IDP-123 Lotion in comparison with IDP-123 Vehicle Lotion.
- Trial name
- NCT03168334
- Testing
- IDP-123 Lotion, IDP-123 Vehicle Lotion
- Where
- 45 sites in United States, Canada
- Volunteers
- 801 people
- Sponsor
- Bausch Health Americas, Inc.
Actinic Keratosis
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on the balding scalp when applied topically once daily for 3 consecutive days as field treatment.
- Trial name
- NCT02547363
- Testing
- LEO 43204 gel, Vehicle gel
- Where
- United States
- Volunteers
- 373 people
- Sponsor
- LEO Pharma
Acne Vulgaris
P3 Study in Acne Comparing Once Daily SB204 and Vehicle
This is a 12 week, multi-center, double-blinded, randomized, vehicle-controlled, parallel group, study to be conducted in approximately 1300 subjects with acne vulgaris in the US.
- Trial name
- NCT02672332
- Testing
- SB204 4%, Vehicle Gel
- Where
- 55 sites in United States
- Volunteers
- 1,307 people
- Sponsor
- Novan, Inc.
Dry Eye Disease
Study Evaluating the Safety and Efficacy of AR-15512
This will be a Phase 3, multicenter, vehicle-controlled, double-masked, randomized study conducted at approximately 20 sites in the United States. All subjects enrolled will have dry eye disease (DED).
- Trial name
- COMET-2 (NCT05285644)
- Testing
- 0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
- Where
- 23 sites in United States
- Volunteers
- 465 people
- Sponsor
- Aerie Pharmaceuticals
Vulvovaginal Atrophy
Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia
The purpose of the study is to determine if WC3011 is safe and effective in treating the symptom of painful intercourse secondary to vulvovaginal atrophy as measured by participant self-assessment when compared to vehicle.
- Trial name
- NCT01845649
- Testing
- WC3011 Estradiol Vaginal Cream, Vehicle
- Where
- 57 sites in United States
- Volunteers
- 550 people
- Sponsor
- Warner Chilcott
Acne Vulgaris
A Study Comparing Two Topicals in the Treatment of Acne Vulgaris
A Randomized, Evaluator-Blinded, Bilateral Comparison Study to Evaluate the Safety and Efficacy of Two Topicals in the Treatment of Subjects With Acne Vulgaris (Study FX2018-23).
- Trial name
- NCT03743038
- Testing
- FMX101 vehicle, Hydro-alcohol solution
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vyne Therapeutics Inc.
Vaginal Infection
Multi-Center Study of New Medications to Treat Vaginal Infections
The purpose of this study is to evaluate the safety and efficacy of metronidazole gel in the treatment of vaginal infections.
- Trial name
- SMART GIVES (NCT02308033)
- Testing
- Metronidazole, Gel vehicle
- Where
- 35 sites in United States
- Volunteers
- 204 people
- Sponsor
- Curatek Pharmaceuticals, LLC
Allergic Conjunctivitis
A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- NCT01685242
- Testing
- AC-170 0.24%, AC-170 0%
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Aciex Therapeutics, Inc.
Heart Failure
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2
LCZ696, a molecular complex of the angiotensin receptor blocker (ARB) valsartan with an inhibitor of neprilysin (NEP, neutral endopeptidase-24.11) sacubitril improved mortality compared to enalapril in patients with heart failure…
- Trial name
- NCT04113109
- Testing
- LCZ 696, Icatibant, Para-aminohippurate
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Vanderbilt University Medical Center
Fatty Liver
Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease
The purpose of this study is to evaluate the effect of GWP42003 on liver triglyceride (liver fat) in participants with fatty liver disease (FLD).
- Trial name
- NCT01284634
- Testing
- GWP42003 200 mg/day Dose, GWP42003 400 mg/day Dose, GWP42003 800 mg/day Dose
- Where
- 3 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- GW Research Ltd
Dry Eye
A Clinical Trial to Assess Subjects With Dry Eye Disease.
A Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
- Trial name
- NCT04971031
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Systemic Lupus Erythematosus Arthritis
Abatacept for SLE Arthritis (IM101-330)
This research trial is for patients who have been diagnosed with systemic lupus erythematosus (SLE) with swollen, tender joints (which is called inflammatory polyarthritis) because of the SLE.
- Trial name
- NCT02429934
- Testing
- abatacept also known as Orencia also known as CTLA4-Ig
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of California, Los Angeles
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.